Tech Company Financing Transactions
Oryzon Genomics Funding Round
Oryzon Genomics closed a $31.9 million financing round on 4/25/2025. Backers included private investors.
Transaction Overview
Company Name
Announced On
4/25/2025
Transaction Type
Venture Equity
Amount
$31,860,000
Round
Undisclosed
Investors
Proceeds Purpose
The funds raised will be used to: Advance the clinical development of vafidemstat for the treatment of aggression in CNS disorders such as Borderline Personality Disorder (BPD) and Autism Spectrum Disorder (ASD)
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Sant Ferran 74
Cornellà de Llobregat, Barcelona, 08940
SE
Cornellà de Llobregat, Barcelona, 08940
SE
Phone
Website
Email Address
Overview
ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Our business model is to develop our proprietary drug candidates through clinical Phase II, at which point we decide on a case-by-case basis to either keep the development in-house or to partner or out-license the compound for late stage development and commercialization. ORYZON has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Carlos Buesa
Chief Medical Officer
Michael Ropacki
Chief Operating Officer
Enric Rello
Chief Scientific Officer
Jordi Xaus
Browse more venture capital transactions:
Prev: 4/25/2025: Emmi AI venture capital transaction
Next: 4/25/2025: Tyneso venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to record all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs